147 related articles for article (PubMed ID: 37116911)
1. Fibroblast Activation Protein-Targeted Radioligand Therapy for Treatment of Solid Tumors.
Lindeman SD; Mukkamala R; Horner A; Tudi P; Booth OC; Huff R; Hinsey J; Hovstadius A; Martone P; Zhang F; Srinivasarao M; Cox A; Low PS
J Nucl Med; 2023 May; 64(5):759-766. PubMed ID: 37116911
[TBL] [Abstract][Full Text] [Related]
2. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
[TBL] [Abstract][Full Text] [Related]
3. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
Poplawski SE; Hallett RM; Dornan MH; Novakowski KE; Pan S; Belanger AP; Nguyen QD; Wu W; Felten AE; Liu Y; Ahn SH; Hergott VS; Jones B; Lai JH; McCann JAB; Bachovchin WW
J Nucl Med; 2024 Jan; 65(1):100-108. PubMed ID: 38050111
[TBL] [Abstract][Full Text] [Related]
5. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.
Wen X; Xu P; Shi M; Liu J; Zeng X; Zhang Y; Shi C; Li J; Guo Z; Zhang X; Khong PL; Chen X
Theranostics; 2022; 12(1):422-433. PubMed ID: 34987657
[No Abstract] [Full Text] [Related]
6.
Li H; Ye S; Li Li ; Zhong J; Yan Q; Zhong Y; Feng P; Hu K
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2705-2715. PubMed ID: 35290473
[TBL] [Abstract][Full Text] [Related]
7. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy.
Xu M; Chen J; Zhang P; Cai J; Song H; Li Z; Liu Z
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3214-3224. PubMed ID: 37318538
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides.
Millul J; Koepke L; Haridas GR; Sparrer KMJ; Mansi R; Fani M
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3050-3061. PubMed ID: 37261473
[TBL] [Abstract][Full Text] [Related]
9. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H
Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy.
Zhang P; Xu M; Ding J; Chen J; Zhang T; Huo L; Liu Z
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1985-1996. PubMed ID: 34746969
[TBL] [Abstract][Full Text] [Related]
11.
Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
[TBL] [Abstract][Full Text] [Related]
12. Development and Characterization of Novel FAP-Targeted Theranostic Pairs: A Bench-to-Bedside Study.
Huang W; Pang Y; Liu Q; Liang C; An S; Wu Q; Zhang Y; Huang G; Chen H; Liu J; Wei W
Research (Wash D C); 2023; 6():0282. PubMed ID: 38706713
[TBL] [Abstract][Full Text] [Related]
13. A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake.
Galbiati A; Zana A; Bocci M; Millul J; Elsayed A; Mock J; Neri D; Cazzamalli S
J Nucl Med; 2022 Dec; 63(12):1852-1858. PubMed ID: 35589404
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.
Zboralski D; Hoehne A; Bredenbeck A; Schumann A; Nguyen M; Schneider E; Ungewiss J; Paschke M; Haase C; von Hacht JL; Kwan T; Lin KK; Lenore J; Harding TC; Xiao J; Simmons AD; Mohan AM; Beindorff N; Reineke U; Smerling C; Osterkamp F
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3651-3667. PubMed ID: 35608703
[TBL] [Abstract][Full Text] [Related]
15. Design and validation of fibroblast activation protein alpha targeted imaging and therapeutic agents.
Roy J; Hettiarachchi SU; Kaake M; Mukkamala R; Low PS
Theranostics; 2020; 10(13):5778-5789. PubMed ID: 32483418
[No Abstract] [Full Text] [Related]
16. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α.
Dekempeneer Y; Massa S; Santens F; Navarro L; Berdal M; Lucero MM; Pombo Antunes AR; Lahoutte T; Van Ginderachter JA; Devoogdt N; D'Huyvetter M
J Nucl Med; 2023 Dec; 64(12):1941-1948. PubMed ID: 38040444
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics.
Galbiati A; Dorten P; Gilardoni E; Gierse F; Bocci M; Zana A; Mock J; Claesener M; Cufe J; Büther F; Schäfers K; Hermann S; Schäfers M; Neri D; Cazzamalli S; Backhaus P
J Nucl Med; 2023 Dec; 64(12):1934-1940. PubMed ID: 37734838
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of
Zhao L; Niu B; Fang J; Pang Y; Li S; Xie C; Sun L; Zhang X; Guo Z; Lin Q; Chen H
J Nucl Med; 2022 Jun; 63(6):862-868. PubMed ID: 34556528
[TBL] [Abstract][Full Text] [Related]
20. Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy.
Jiang L; Miao Z; Kimura RH; Liu H; Cochran JR; Culter CS; Bao A; Li P; Cheng Z
Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):613-22. PubMed ID: 21153409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]